No announcement yet.

Expert Rev Vaccines . Vaccines against SARS-CoV-2 variants and future pandemics

  • Filter
  • Time
  • Show
Clear All
new posts

  • Expert Rev Vaccines . Vaccines against SARS-CoV-2 variants and future pandemics

    Expert Rev Vaccines

    . 2022 Aug 4.
    doi: 10.1080/14760584.2022.2110075. Online ahead of print.
    Vaccines against SARS-CoV-2 variants and future pandemics

    Taeyoung Park 1 , Hyogyeong Hwang 1 , Suhyeong Moon 1 , Sang Gu Kang 1 , Seunghyup Song 1 , Young Hun Kim 1 , Hanbi Kim 1 , Eun-Ju Ko 2 , Soon-Do Yoon 3 , Sang-Moo Kang 4 , Hye Suk Hwang 1



    Introduction: Vaccination continues to be the most effective method for controlling COVID-19 infectious diseases. Nonetheless, SARS-CoV-2 variants continue to evolve and emerge, resulting in significant public concerns worldwide even after more than two years since the COVID-19 pandemic. It is significant to better understand how different COVID-19 vaccine platforms work, why SARS-CoV-2 variants continue to emerge, and what options for improving COVID-19 vaccines can be considered to fight against SARS-CoV-2 variants and future pandemics.
    Area covered: Here, we reviewed the innate immune sensors in the recognition of SARS-CoV-2 virus, innate and adaptive immunity including neutralizing antibodies by different COVID-19 vaccines. Efficacy comparison of the several COVID-19 vaccine platforms approved to use in humans, concerns about SARS-CoV-2 variants and breakthrough infections, and the options for developing future COIVD-19 vaccines were also covered.
    Expert opinion: Owing to the continuous emergence of novel pathogens and the re-emergence of variants, safer and more effective new vaccines are needed. This review is also aimed to provide the knowledge basis for the development of next-generation COVID-19 and pan-coronavirus vaccines to provide cross-protection against new SARS-CoV-2 variants and future coronavirus pandemics.

    Keywords: SARS-CoV-2: ACE-2; TMPRSS-2; nucleic acid-based vaccine; universal vaccine.